Cargando…

PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer

Clinical trials have demonstrated the efficacy of combining phosphoinositide 3-kinase (PI3K) inhibitors with endocrine therapies in hormone therapy-refractory breast cancer. However, biomarkers of PI3K pathway dependence in ER+ breast cancer have not been fully established. Hotspot mutations in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nixon, Mellissa J., Formisano, Luigi, Mayer, Ingrid A., Estrada, M. Valeria, González-Ericsson, Paula I., Isakoff, Steven J., Forero-Torres, Andrés, Won, Helen, Sanders, Melinda E., Solit, David B., Berger, Michael F., Cantley, Lewis C., Winer, Eric P., Arteaga, Carlos L., Balko, Justin M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757060/ https://www.ncbi.nlm.nih.gov/pubmed/31552290 http://dx.doi.org/10.1038/s41523-019-0126-6

Ejemplares similares

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
por: Garrido-Castro, Ana C., et al.
Publicado: (2020)

Buparlisib is a brain penetrable pan-PI3K inhibitor
por: de Gooijer, Mark C., et al.
Publicado: (2018)

Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention
por: Bohnacker, Thomas, et al.
Publicado: (2017)

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
por: Lehmann, Brian D, et al.
Publicado: (2014)

PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer
por: Loi, Sherene, et al.
Publicado: (2013)

Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas
por: Anderson, Jennifer L., et al.
Publicado: (2015)

Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study
por: Piha-Paul, Sarina A., et al.
Publicado: (2019)

Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer
por: Loi, Sherene, et al.
Publicado: (2019)

PIK3CA(H1047R) and Her2 initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling
por: Cheng, Hailing, et al.
Publicado: (2015)

Pik3ip1 Modulates Cardiac Hypertrophy by Inhibiting PI3K Pathway
por: Song, Hong Ki, et al.
Publicado: (2015)

The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging
por: Wang, Shengfei, et al.
Publicado: (2019)

The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines
por: Ma, Yixuan, et al.
Publicado: (2022)

Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers
por: Engelman, Jeffrey A., et al.
Publicado: (2008)

The Mammalian Class 3 PI3K (PIK3C3) Is Required for Early Embryogenesis and Cell Proliferation
por: Zhou, Xiang, et al.
Publicado: (2011)

PIK3C3 regulates the expansion of liver CSCs and PIK3C3 inhibition counteracts liver cancer stem cell activity induced by PI3K inhibitor
por: Liu, Fengchao, et al.
Publicado: (2020)

PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors
por: Payne, S N, et al.
Publicado: (2015)

Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats
por: Netland, I. A., et al.
Publicado: (2016)

The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer
por: Cataldo, Maria Letizia, et al.
Publicado: (2023)

Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer
por: Lee, Kyung-min, et al.
Publicado: (2020)

Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor‐positive, HER2‐negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression
por: Welt, Anja, et al.
Publicado: (2020)

Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis
por: Ramirez-Ardila, Diana, et al.
Publicado: (2017)

Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors
por: Ando, Yuichi, et al.
Publicado: (2014)

Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer
por: Avivar-Valderas, Alvaro, et al.
Publicado: (2018)

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
por: Younes, Anas, et al.
Publicado: (2017)

H3K27me3 Profiling of the Endosperm Implies Exclusion of Polycomb Group Protein Targeting by DNA Methylation
por: Weinhofer, Isabelle, et al.
Publicado: (2010)

The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase
por: Hoeflich, Klaus P., et al.
Publicado: (2016)

PIK3CA Gene Amplification and PI3K p110α Protein Expression in Breast Carcinoma
por: Firoozinia, Mohammad, et al.
Publicado: (2014)

PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition
por: McNeill, Robert S., et al.
Publicado: (2018)

PIK3IP1/TrIP restricts activation of T cells through inhibition of PI3K/Akt
por: Uche, Uzodinma U., et al.
Publicado: (2018)

Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer
por: Malentacchi, Francesca, et al.
Publicado: (2019)

BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma
por: Speranza, Maria-Carmela, et al.
Publicado: (2016)

Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer
por: Liu, Qi, et al.
Publicado: (2023)

Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations
por: Leontiadou, Hari, et al.
Publicado: (2018)

Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers
por: Fang, Wen-Liang, et al.
Publicado: (2015)

A Ras-LSD1 axis activates PI3K signaling through PIK3IP1 suppression
por: Lee, Kyunghee, et al.
Publicado: (2020)

Somatic Mutations of PIK3R1 Promote Gliomagenesis
por: Quayle, Steven N., et al.
Publicado: (2012)

Distribution of K(v)3 Subunits in Cochlear Afferent and Efferent Nerve Fibers Implies Distinct Role in Auditory Processing
por: Kim, Woo Bin, et al.
Publicado: (2020)

Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen
por: Chen, I-Chun, et al.
Publicado: (2017)

The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients
por: Hayama, Shouko, et al.
Publicado: (2023)

Coexistent ARID1A-PIK3CA mutations are associated with immune-related pathways in luminal breast cancer
por: Anabel Sinberger, Liat, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_90ffmbd8hlekd91rsp1tfn1cdj